Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified July 2026 by Stichting Hemato-Oncologie voor Volwassenen Nederland
Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Information Provided by (Responsible Party)
Stichting Hemato-Oncologie voor Volwassenen Nederland
Clinicaltrials.gov Identifier
NCT06652438
Other Study ID Numbers:
HO177
First Submitted
October 1, 2024
First Posted
October 21, 2024
Last Update Posted
September 1, 2026
Last Verified
July 2026

ClinicalTrials.gov processed this data on August 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Acute Myeloid Leukemia, Adult
Drug: PlaceboDrug: Revumenib

Study Design

Study TypeInterventional
Actual Enrollment448 participants
Design AllocationRandomized
Interventional ModelSingle Group Assignment
MaskingTriple
Primary PurposeTreatment
Official TitleRandomized Study to Assess Revumenib in Combination With Azacitidine + Venetoclax in Adult Patients With Newly Diagnosed NPM1-mutated or KMT2A-rearranged AML Ineligible for Intensive Chemotherapy
Study Start DateMay 4, 2025
Actual Primary Completion Date3yrs 3mos from now
Actual Study Completion Date5yrs 11mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Revumenib-placebo
day 1-28 Placebo Treatment will be on a continuous 28-day cycle schedule and continued until disease progression, development of unacceptable toxicity, death, withdrawal by subject or other protocol defined criteria for discontinuation (whichever comes first).
Drug: Placebo
day 1- 28 per cycle
Revumenib
day 1-28 Revumenib Treatment will be on a continuous 28-day cycle schedule and continued until disease progression, development of unacceptable toxicity, death, withdrawal by subject or other protocol defined criteria for discontinuation (whichever comes first).
Drug: Revumenib
day 1- 28 per cycle

Outcome Measures

Primary Outcome Measures
  1. Overall survival (OS) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy.
    To assess if treatment with revumenib, in combination with azacitidine and venetoclax, prolongs overall survival (OS) measured from the date of randomization to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.
  2. Rate of CR in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    Defined as the proportion of NPM1-mutated AML patients who achieve CR at any time-point during protocol therapy.
Secondary Outcome Measures
  1. Event-free survival (EFS) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy.
    Assess if treatment with revumenib, in combination with azacitidine and venetoclax, prolongs event-free survival (EFS); measured from the date of randomization to the date of treatment failure, hematologic relapse from CR/CRh or death from any cause, whichever occurs first. Treatment failure is defined as lack of obtaining either CR or CRh by week 24.
  2. Rate of CR/CRh in adult patients with newly diagnosed NPM1mutated AML ineligible for intensive chemotherapy,
    Defined as the proportion of NPM1-mutated AML patients who achieve CR or CRh at any time-point during protocol therapy.
  3. Rate of response (CRh and CR/CRi) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    Rate of response (CRh and CR/CRi) is defined as the proportion of patients with response at any time-point during protocol therapy.
  4. Rates of CRMRD-, CR/CRhMRD-, and CR/CRiMRD- assessed by quantitative PCR of bone marrow in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    defined as the proportion of NPM1-mutated AML patients with CRMRD-, CR/CRhMRD- and CR/CRiMRD- by PCR of bone marrow, respectively, at any time-point during protocol therapy.
  5. Rates of CRMRD-, CR/CRhMRD-, and CR/CRiMRD- assessed by quantitative PCR of peripheral blood in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    defined as the proportion of NPM1-mutated AML patients with CRMRD-, CR/CRhMRD- and CR/CRiMRD- by PCR of peripheral blood, respectively, at any time-point during protocol therapy.
  6. Time to achievement of response (CR, CR/CRh and CR/CRi) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    measured as the time from randomization to 1st occurrence of response.
  7. Duration of response (CR, CR/CRh and CR/CRi; DoR) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    measured from the date of achievement of response until the date of hematologic relapse or death from any cause.
  8. QoL in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores are transformed to a 0 to 100 scale. For the Global Health Status/Quality of Life scale and functional scales, higher scores indicate better quality of life/functioning; for symptom scales, higher scores indicate worse symptoms.
  9. QoL in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy
    Health-related quality of life was assessed using the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L). The EQ-5D-5L descriptive system generates a health utility index score based on country-specific value sets. Higher utility values indicate better health status. The EQ Visual Analogue Scale (EQ VAS), if reported, ranges from 0 to 100, where higher scores indicate better perceived health.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
In order to be eligible to participate in this study, a patient must meet all of the following criteria: 1. Patient with newly diagnosed NPM1-mutated AML, consistent with NPM1c, according to the 2022 International Consensus Classification (i.e. ≥ 10% blasts). OR Patient with newly diagnosed KMT2A-rearranged AML according to the 2022 International Consensus Classification (i.e. ≥ 10% blasts). KMT2A partial tandem duplications or deletions are NOT eligible. Of note: in case both NPM1 and IDH1 are mutated and both EVOLVE-1 (HO173) and EVOLVE-2 (HO177) are open for inclusion at your site, then patients can only be included in the EVOLVE-1 trial (HO173) 2. Central confirmation of NPM1 mutation or KMT2A rearrangement in one of the dedicated central genetic laboratories. 3. Age ≥ 18 years, no upper age limit. 4. Patient is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:
≥ 75 years of age: ineligible for intensive chemotherapy per physician's discretion (with an ECOG performance status 0-2) .
18-74 years: patient is not eligible for standard chemotherapy because any of the following co-morbidities:
ECOG performance status 2 or 3 .
Cardiac history of chronic heart failure requiring treatment; or with an ejection fraction ≤50%; or chronic stable angina.
DLCO ≤ 65% or FEV1 ≤ 65%.
Creatinine clearance ≥ 30 mL/min to \<45 ml/min calculated by the Cockcroft Gault formula.
Moderate hepatic impairment with total bilirubin \> 1.5 to \< 3.0 x upper limit of normal (ULN).
Any other comorbidity that the local physician assesses to be incompatible with intensive chemotherapy must be reviewed and approved by the Sponsor's (co-) Principal Investigator (written approval must be sent to HO177@erasmusmc.nl before study enrolment). 5. Patient must have a projected life expectancy of at least 12 weeks (as assessed by the treating physician). 6. Patient must have a white cell blood (WBC) count of \< 25 x 109/L. Hydroxyurea can be used prior to study enrolment to reduce the WBC count to meet this criterion. 7. Adequate renal function as evidenced by serum creatinine ≤ 2.0 × upper limit of norm (ULN) or creatinine clearance \>30 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR). 8. Adequate hepatic function as evidenced by:
Serum total bilirubin ≤ 3.0 × ULN unless considered due to Gilbert's disease, or leukemic involvement following written approval by the sponsor (Co-)Principal Investigator (copy in HO177@erasmusmc.nl).
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement following written approval by the sponsor (Co-)Principal Investigator (copy in HO177@erasmusmc.nl). 9. Female patient must:
be of nonchildbearing potential: o postmenopausal (defined as at least 1 year without any menses). o documented surgically sterile (e.g. documented hysterectomy, bilateral oophorectomy, bilateral salpingectomy or congenital sterile) or status post hysterectomy (at least 1 month prior to screening).
or, if of childbearing potential (not surgically sterile and not postmenopausal) agree to avoid pregnancy during the study and for 6 months after the final study drug administration.
and have a negative urine or serum pregnancy test at screening.
and, if heterosexually active, agree to consistently apply one highly effective\
method of birth control in combination to a barrier method for the duration of the study and for 6 months after the final study drug administration. \
Highly effective forms of birth control include \- Consistent and correct usage of established hormonal contraceptives that inhibit ovulation for at least 1 month prior to taking study drug. (hormonal contraception is only a highly effective method of birth control, if a combined \[estrogen and progestogen containing\] hormonal contraception or a progestogen-only hormonal contraception - both associated with inhibition of ovulation - is used. \- Established intrauterine device (IUD) or intrauterine system (IUS) \- Bilateral tubal occlusion \- Vasectomy - a vasectomy is highly effective contraception method provided the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. \- Male is sterile due to a bilateral orchiectomy.
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual activity during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. List is not all inclusive. Prior to enrolment, the investigator is responsible for confirming patient will utilize highly effective forms of birth control in combination with a barrier method according to locally accepted standards during the protocol defined period.
agree not to breastfeed starting at screening and throughout the study period.
agree not to donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration. 10. Men must use a latex condom during any sexual contact with women of childbearing potential (WOCBP), even if they have undergone a successful vasectomy and must agree to avoid to father a child (while on therapy and for 6 months after the final study drug administration). In addition, their female partners of childbearing potential must use a highly effective method of birth control. 11. Male patient must not donate sperm starting at screening and throughout the study period and for 6 months after the final study drug administration. 12. Able to understand and willing to sign an informed consent form (ICF). 13. Institutional Review Board/Independent Ethics Committee-approved written informed consent as per national regulations must be obtained from the patient prior to any study-related procedures (including consent for withdrawal of prohibited medication, if applicable).
Exclusion Criteria
Subject has previously been treated for AML; a treatment period with hydroxyurea to control WBC counts is allowed; prior treatment with a hypomethylating agent for MDS-EB is not allowed; prior treatment with erythropoiesis-stimulating agents or luspatercept for MDS is allowed. 2\. Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2); PML-RARA; or one of the other pathognomonic variant chromosomal translocations / fusion genes. 3. AML with BCR-ABL1; or myeloid blast crisis of CML. 4. Significant active cardiac disease within 3 months prior to the start of study treatment, including:
New York Heart Association (NYHA) class III or IV congestive heart failure
Myocardial infarction
Unstable angina
Severe cardiac arrhythmias
Congenital long QT syndrome of family member with this condition QTcF \>450 msec on screening electrogram for males and \>470msec on screening electrogram for females (mean of triplicate recordings; calculated using Fridericia's correction). 5. Severe obstructive or restrictive ventilation disorder. 6. History of stroke or intracranial hemorrhage within 6 months prior to randomization. 7\. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only required if there is a clinical suspicion of CNS involvement by leukemia during screening. 8. Active infection, including hepatitis B or hepatitis C or Human Immunodeficiency Virus (HIV) infection, that is uncontrolled prior to first dose of study treatment and may interfere with the study objectives or which could expose the patient to undue risk through the participation in the clinical trial; an infection controlled with an approved antibiotic/ antiviral/ antifungal treatment that is not a strong or moderate CYP3A inducer is allowed. Patients with COVID-19 infection can be enrolled, if the patient has no symptoms and was tested negative twice by PCR test prior to inclusion in the trial. 9. Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding and/or disseminated intravascular coagulation. 10. Conditions that limit the ingestion or gastrointestinal absorption of orally administered drugs. 11\. Patient with a currently active second malignancy. Patients are not considered to have a currently active malignancy, if they have completed therapy and are considered by their physician to be at \< 30% risk of relapse within one year. However, patients with the following history/concurrent conditions are allowed:
Basal or squamous cell carcinoma of the skin;
Carcinoma in situ of the cervix;
Carcinoma in situ of the breast;
Incidental histologic finding of prostate cancer. 12. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE: patient, if enrolled, should not receive live vaccine during the study and until 6 months after the therapy). 13\. Severe neurological or psychiatric disorder interfering with ability to give an informed consent. 14\. Contraindication to AZA or VEN (as per Summary of Product Characteristics (SmPC)). 15\. Patient weighing \<40 kg at registration. 16. Participation in other prospective studies with anti-leukemic and/or investigational agents. 17\. Patient taking Dabigatran unless they can be transferred to other medications within ≥5 half-lives prior to dosing. Patients taking other P-gP transporter-sensitive medications (see Appendix H) should be properly monitored during the study if they cannot be transferred to other medications. 18\. Patient taking known strong cytochrome P450 (CYP) 3A4 inducers (see Appendix G), unless they can be transferred to other medications within ≥5 half-lives prior to dosing. 19\. The patient is a pregnant or lactating woman, or plans to become pregnant during the study. 20\. Patient who has once been screened and randomized into this HO177 trial but was considered ineligible cannot re-enter this trial at a later date.

Contacts and Locations

Sponsors and CollaboratorsStichting Hemato-Oncologie voor Volwassenen Nederland
Locations
US-Los Angeles CA-UCLA | Los Angeles California, United States, 90095US-San Francisco CA-UCSF | San Francisco California, United States, 94143US-Jacksonville FL-MAYOFL | Jacksonville Florida, United States, 32224US-Atlanta GA-EMORY | Atlanta Georgia, United States, 30322US-Kansas City KS-KUMC | Fairway Kansas, United States, 66205US-Baltimore MD-UMGCCC | Baltimore Maryland, United States, 21201US-Rochester MN-MAYOMN | Rochester Minnesota, United States, 55905US-Chapel Hill-UNCNORTHCAROLINA | Chapel Hill North Carolina, United States, 27514US-Cincinnati OH-CINCY | Cincinnati Ohio, United States, 45219US-Colombus OH-OSU | Columbus Ohio, United States, 43210US-Portland OR-OHSU | Portland Oregon, United States, 97239US-Pittsburgh PA-PITT | Pittsburgh Pennsylvania, United States, 15232US-Dallas TX-SOUTHWESTERN | Dallas Texas, United States, 75390US-Wheeling WV-WVU | Wheeling West Virginia, United States, 26003AU-Adelaide-RAH | Adelaide , Australia, AU-Birtinya-SUNSHINECOASTUH General Information | Birtinya , Australia, AU-Brisbane-RBWH | Brisbane , Australia, AU-Douglas-TOWNSVILLE | Douglas , Australia, AU-Melbourne-ALFRED | Melbourne , Australia, AU-Melbourne-MONASH | Melbourne , Australia, AU-Perth-FSH | Perth , Australia, AU-Perth-SCGH | Perth , Australia, AU-Sydney-RNSH | Sydney , Australia, AU-Sydney-SVSH | Sydney , Australia, AT-Feldkirch-IKHF | Feldkirch , Austria, AT-Linz-KEPLER | Linz , Austria, AT-Salzburg-SALK | Salzburg , Austria, AT-Vienna-HANUSCH | Vienna , Austria, BE-Antwerpen-ZAS | Antwerp , Belgium, BE-Brugge-AZBRUGGE | Bruges , Belgium, BE-Brussel-BORDET | Brussels , Belgium, BE-Brussel-UZBRUSSEL | Brussels , Belgium, BE-Bruxelles-STLUC | Brussels , Belgium, BE-Gent-UZGENT | Ghent , Belgium, BE-Hasselt-VIRGAJESSE | Hasselt , Belgium, BE-Leuven-UZLEUVEN | Leuven , Belgium, BE-Liege-CHULIEGE | Liège , Belgium, BE-Yvoir-MONTGODINNE | Yvoir , Belgium, DK-Aalborg-AALBORGUH | Aalborg , Denmark, DK-Aarhus N-AUH | Aarhus N , Denmark, DK-Copenhagen-RIGSHOSPITALET | Copenhagen , Denmark, DK-Odense-OUH | Odense , Denmark, EE-Tallinn-REGIONAALHAIGLA | Tallinn , Estonia, EE-Tartu-TARTU | Tartu , Estonia, FI-Helsinki-HUS | Helsinki , Finland, FI-Oulu-OYS | Oulu , Finland, FI-Tampere-TAYS | Tampere , Finland, FI-Turku-TYKS | Turku , Finland, FR-Amiens-CHUAMIENS | Amiens , France, FR-Angers-CHUANGERS | Angers , France, FR-Bayonne-CHCOTEBASQUE | Bayonne , France, FR-Besançon Cedex-JEANMINJOZ | Besançon , France, FR-Caen-CHUCAEN | Caen , France, FR-Clamart-HIAPERCY | Clamart , France, FR-Clermont Ferrand-ESTAING | Clermont-Ferrand , France, FR-Créteil cedex-CHUMONDOR | Créteil , France, FR-Grenoble cedex 9-CHUGRENOBLE | Grenoble , France, FR-Le Chesnay cedex-CHVERSAILLES | Le Chesnay , France, FR-Lille-CHULILLE | Lille , France, FR-Limoges-CHULIMOGES | Limoges , France, FR-Metz-Cedex-MERCY | Metz , France, FR-Montpellier-STELOI | Montpellier , France, FR-Nantes-CHUNANTES | Nantes , France, FR-Nice-LARCHET | Nice , France, FR-Pessac Cedex-CHUBORDEAUX | Pessac , France, FR-Lyon Pierre Benite cedex-LYONSUD | Pierre-Bénite , France, FR-Rouen cedex-BECQUEREL | Rouen , France, FR-Saint-Priest-en-Jarez-STETIENNE | Saint-Priest-en-Jarez , France, FR-Strasbourg cedex-HAUTEPIERRE | Strasbourg , France, DE-Berlin-CAMPUSBENFRANKLIN | Berlin , Germany, DE-Berlin-CAMPUSVIRCHOW | Berlin , Germany, DE-Berlin-VIVANTESNEUKOLLN | Berlin , Germany, DE-Bochum-RUB | Bochum , Germany, DE-Bonn-UNIBONN | Bonn , Germany, DE-Braunschweig-KLINIKUMBRAUNSCHWEIG | Braunschweig , Germany, DE-Bremen-KBM | Bremen , Germany, DE-Darmstadt-KLINIKUMDARMSTADT | Darmstadt , Germany, DE-Essen-KEM | Essen , Germany, DE-Flensburg-MALTESER | Flensburg , Germany, DE-Freiburg-UNIKLINIKFREIBURG | Freiburg im Breisgau , Germany, DE-Greifswald-UNIGREIFSWALD | Greifswald , Germany, Halle-UMH | Halle , Germany, DE-Hamburg-ASKLEPIOSSTGEORG | Hamburg , Germany, DE-Hamburg-UKE | Hamburg , Germany, DE-Hannover-MHHANNOVER | Hanover , Germany, DE-Heilbronn-SLK General Information | Heilbronn , Germany, DE-Herne-MARIENHOSPITALHERNE | Herne , Germany, DE-Karlsruhe-KLINIKUMKARLSRUHE | Karlsruhe , Germany, DE-Magdeburg-OVGU | Magdeburg , Germany, DE-Mainz-UNIMEDIZINMAINZ | Mainz , Germany, DE-Minden-MUEHLENKREISKLINKEN | Minden , Germany, DE-München-IRZTUM | München , Germany, DE-Oldenburg-KLINIKUMOLDENBURG | Oldenburg , Germany, DE-Potsdam-BERGMANN | Potsdam , Germany, DE-Regensburg-UKR | Regensburg , Germany, DE-Rostock-MUROSTOCK | Rostock , Germany, DE-Stuttgart-KLINIKUMSTUTTGART | Stuttgart , Germany, DE-Tübingen-MEDUNITUEBINGEN | Tübingen , Germany, DE-Ulm-UNIKLINKULM | Ulm , Germany, DE-Wuppertal-HELIOSGESUNDHEIT | Wuppertal , Germany, IE-Cork-CUH | Cork , Ireland, IE-Dublin 4-SVUH | Dublin , Ireland, IE-Dublin 7-MATER | Dublin , Ireland, IE-Dublin 8-STJAMES | Dublin , Ireland, IE-Dublin 9-BEAUMONT | Dublin , Ireland, IE-Galway-UHGALWAY | Galway , Ireland, IE-Waterford City-WATERFORD | Waterford , Ireland, IT-Ancona-MARCHE | Ancona , Italy, IT-Bologna-MALPHIGI | Bologna , Italy, IT-Civitanova Marche-AZURZONA | Civitanova Marche , Italy, IT-Milano-NIGUARDA | Milan , Italy, IT-Pagani-TORTORA | Pagani , Italy, IT-Palermo-CERVELLO | Palermo , Italy, IT-Perugia-OSPEDALEPERUGIA | Perugia , Italy, IT-Pescara-AUSLPESCARA | Pescara , Italy, IT-Roma-SAPIENZA | Roma , Italy, IT-Roma-TORVERGATA | Roma , Italy, IT-Torino-CITTADELLASALUTE | Torino , Italy, IT-Trieste-MAGGIORETRIESTE | Trieste , Italy, LT-Vilnius-SANTA | Vilnius , Lithuania, NL-Den Bosch-JBZ | 's-Hertogenbosch , Netherlands, NL-Amersfoort-MEANDERMC | Amersfoort , Netherlands, Amsterdamumc | Amsterdam , Netherlands, NL-Amsterdam-OLVG | Amsterdam , Netherlands, NL-Arnhem-RIJNSTATE | Arnhem , Netherlands, NL-Breda-AMPHIA | Breda , Netherlands, NL-Delft-RDGG | Delft , Netherlands, NL-Dordrecht-ASZ | Dordrecht , Netherlands, NL-Dordrecht-ASZ | Dordrecht , Netherlands, NL-Eindhoven-MAXIMAMC | Eindhoven , Netherlands, NL-Enschede-MST | Enschede , Netherlands, NL-Goes-ADRZ | Goes , Netherlands, NL-Groningen-UMCG | Groningen , Netherlands, NL-Leeuwarden-FRISIUSMC | Leeuwarden , Netherlands, NL-Leiden-LUMC | Leiden , Netherlands, NL-Maastricht-MUMC | Maastricht , Netherlands, NL-Nieuwegein-ANTONIUS | Nieuwegein , Netherlands, NL-Nijmegen-RADBOUDUMC | Nijmegen , Netherlands, NL-Rotterdam-ERASMUSMC | Rotterdam , Netherlands, NL-Den Haag-HAGA | The Hague , Netherlands, NL-Utrecht-UMCUTRECHT | Utrecht , Netherlands, NL-Zwolle-ISALA | Zwolle , Netherlands, NO-Bergen-HELSEBERGEN | Bergen , Norway, NO-Drammen-VESTREVIKEN | Drammen , Norway, NO-Lørenskog-AKERSHUS | Lørenskog , Norway, NO-Oslo-OSLOUH | Oslo , Norway, NO-Stavanger-HELSESTAVANGER | Stavanger , Norway, NO-Tromsø-NORTHNOORWEGEN | Tromsø , Norway, NO-Trondheim-STOLAV | Trondheim , Norway, ES-Alicante-BALMIS | Alicante , Spain, ES-Barcelona-CLINICUB | Barcelona , Spain, ES-Barcelona-GERMANTRIALS | Barcelona , Spain, ES-Barcelona-ICODURANREYNALS | Barcelona , Spain, ES-Barcelona-MUTUATERRASSA | Barcelona , Spain, ES-Barcelona-PARCDESALUTMAR | Barcelona , Spain, ES-Barcelona-SANTPAU | Barcelona , Spain, ES-Girona-ICOGIRONA | Girona , Spain, ES-Lleida-ICSVILANOVA | Lleida , Spain, ES-Madrid-CSGREGORIOMARANON | Madrid , Spain, ES-Palma-SSIB | Palma de Mallorca , Spain, ES-Tarragona-JOAN | Tarragona , Spain, ES-Valencia-MALVARROSA | Valencia , Spain, SE-Goteborg-SAHLGRENSKA | Gothenburg , Sweden, SE-Lund-SUH | Lund , Sweden, SE-Stockholm-KAROLINSKAHUDDINGE | Stockholm , Sweden, SE-Uppsala-UPPSALAUH | Uppsala , Sweden, CH-Aarau-KSA | Aarau , Switzerland, CH-Basel-USB | Basel , Switzerland, CH-Bellinzona-IOSI | Bellinzona , Switzerland, CH-Bern-INSEL | Bern , Switzerland, CH-Geneve (14)-HCUGE | Geneva , Switzerland, CH-Zürich-USZ | Zurich , Switzerland, Belfasttrust | Belfast , United Kingdom, Birmingham-QE | Birmingham , United Kingdom, Blackpool Victoria | Blackpool , United Kingdom, UK-Bodelwyddan-BCUHB | Bodelwyddan , United Kingdom, UK-Bristol-BRISTOLCENTRE | Bristol , United Kingdom, University Hospital of Wales | Cardiff , United Kingdom, UK-Portsmouth-QUEENALEXANDRA | Cosham , United Kingdom, UK-Coventry-UHCOVENTRYANDWARWICKSHIRE | Coventry , United Kingdom, UK-Derby-ROYALDERBYHOSPITAL | Derby , United Kingdom, UK-Edinburgh-WGH | Edinburgh , United Kingdom, Beatson West of Scotland Cancer Centre | Glasgow , United Kingdom, UK-Harrow-NORTHWICK | Harrow , United Kingdom, UK-Hull-CASTLEHILL | Hull , United Kingdom, St. James UH | Leeds , United Kingdom, University Hospitals of Leicester NHS Trust | Leicester , United Kingdom, King's College Hospital | London , United Kingdom, St Bartholomew's Hospital | London , United Kingdom, University College Hospital | London , United Kingdom, Christie NHS Foundation Trust | Manchester , United Kingdom, UK-Manchester-ROYALINFIRMARY | Manchester , United Kingdom, The Newcastle upon Tyne Hospitals NHS Foundation Trust | Newcastle , United Kingdom, Nottingham University Hospitals NHS Trust | Nottingham , United Kingdom, Churchill Hospital, Oxford | Oxford , United Kingdom, Southampton General Hospital | Southampton , United Kingdom, UK-Stoke on Trent-UHNM | Stoke-on-Trent , United Kingdom, The Royal Marsden NHSFT | Sutton , United Kingdom, UK-Swindon-GWH | Swindon , United Kingdom, UK-Cornwall-RCH | Truro , United Kingdom, New cross hospital wolverhampton | Wolverhampton , United Kingdom,
Investigators
Principal Investigator: Gerwin Huls, MD, UMCG/ HOVON